Global Lung Cancer Therapeutics Market: Increasing Cases of Cancer Augments the Market Growth

Lung Cancer Therapeutics Market

Lung cancer is a type of cancer that reduces the efficacy of the lungs to supply the bloodstream with oxygen.  The main factors which are responsible for the lung cancer are cigar smoking, asbestos exposure, cigarette smoking, and other. As per the size which can be checked with the microscope, these cancers can be differentiated. Some of the common symptoms of lung cancer are headache, bone pain, shortness of breath, chest pain, coughing up blood, and hoarseness. According to doctor, lung cancer usually damages the cells that line the lungs. Lung cancers are of two types non- small cell lung cancer, and small cell lung cancer. These cancers can be treated by various therapies such as radiation therapy, chemotherapy, vaccines, and immunotherapies.

Access Full Report at

Some of the factors responsible for the growth of Lung Cancer Therapeutics Market:

  • Increasing cases of lung cancer: There is tremendous increase in the cases of lung cancer worldwide. Every year around 1.6 million deaths are caused due to cancer. Lung cancer is commonly caused by smoking, asbestos, radon and other pollutants. There are certain contaminants present at home and at work that can raise the cancer risk such as asbestos, arsenic, diesel exhaust, and certain sources of silica and chromium. This is the factor due to which non- smokers also get cancer. This is the factor due to which there is increase in the demand for lung cancer treatment worldwide
  • Growing number of smokers: Smoking is considered as the major factor which causes lung cancer. About 5 million deaths a year are caused by smoking-related disease. They have the ability to cause small cell and non- small cell cancer. Increasing number of cigarettes the person smoke each day also increases the risk of cancer. This is another factor which increases the risk of cancer and enhances the demand for cancer treatment

The global lung cancer therapeutics market is segmented on the basis of cancer type as non-small cell lung cancer, metastatic lung cancer, pulmonary neuroendocrine tumors, mediastinal tumors, mesothelioma, & chest wall tumors; molecule type as small molecules, & biologics; drug class as alkylating agents, antimetabolites, EGFR inhibitors, mitotic inhibitors, multikinase inhibitors, & others; treatment type as chemotherapy, radiation therapy, targeted therapy, immunotherapy, others; therapy type as single drug therapy, combination therapy; end user as hospitals, homecare, speciality clinics,& others and distribution channel as hospital pharmacy, retail pharmacy, online among others.

Some of the launches and acquisition in the Lung Cancer Therapeutics Market are:

  • In June 2019, Biodesix, Inc announced the acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test. The extensive experience and patent portfolio of Oncimmune in autoantibodies and their relationship with cancer has inspired the company to consider the use of Oncimmune's EarlyCDT Lung test as a strategic extension to our U.S. diagnostic test package. This acquisition will help the company to enhance their portfolio and strengthen their market position
  • In February 2019, AdoRx Therapeutics announced that they will partner with Johnson & Johnson so they can create lung cancer treatments. The new collaboration aims at developing treatments using the fit-for-use antagonists of AdoRx receptors. They are designed to modulate the effects of high levels of adenosine seen in the tumor microenvironment, which allows the immune system to evade cancer

“According to Data Bridge Market Research, Global Lung Cancer Therapeutics Market healthy CAGR of 12.4% in the forecast period of 2019 to 2026”

Some of the prominent players operating in this market are Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company., AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., CELGENE CORPORATION, AMGEN INC., Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., and many others.

Increasing health tourism and growing government initiatives so they can launch new drugs for lung treatment will accelerate the market growth. Increasing demand for early lung cancer diagnosis and treatment is another factor which is affecting the market growth. Technological advancement and development in the healthcare sector along with the availability of advanced medicine will also affect the market positively in future.

Browse in Healthcare Reports@